Adenuric (febuxostat) is indicated for the treatment of gout. When Adenuric was introduced in Europe in 2009 it was the first xantineoxidase-inhibitor since allopurinol, launched in 1964. Gout is a condition which is underdiagnosed and undertreated. With more treatment alternatives more patient can be treated and painful gout attacks can be prevented.

Adenuric was launched in Denmark 2012 and in Norway and Sweden in 2016.

Adenuric (febuxostat), Tablet, Rx, F

ATC code

Indication area
Treatment of chronic hyperuricaemia in conditions in adults where urate deposition has already occurred (including a history, or presence of, tophus and/or gouty arthritis).

Pharmaprim (Product website)

Last SPC review

Reimbursed when treatment with Allopurinol is contraindicated or not tolerated.

Treatment with febuxostat in patients with pre-existing major cardiovascular diseases (e.g. myocardial infarction, stroke or unstable angina) should be avoided, unless no other therapy options are appropriate. A numerical greater incidence of investigator-reported cardiovascular APTC events (defined endpoints from the Anti-Platelet Trialists’ Collaboration (APTC) including cardiovascular death, non-fatal myocardial infarction, non-fatal stroke) was observed in the febuxostat total group compared to the allopurinol group in the APEX and FACT studies (1.3 vs. 0.3 events per 100 Patient Years (PYs)), but not in the CONFIRMS study (see section 5.1 for detailed characteristics of the studies). The incidence of investigator-reported cardiovascular APTC events in the combined Phase 3 studies (APEX, FACT and CONFIRMS studies) was 0.7 vs. 0.6 events per 100 PYs. In the long-term extension studies the incidences of investigator-reported APTC events were 1.2 and 0.6 events per 100 PYs for febuxostat and allopurinol, respectively. No statistically significant differences were found and no causal relationship with febuxostat was established. Identified risk factors among these patients were a medical history of atherosclerotic disease and/or myocardial infarction, or of congestive heart failure. In the post registrational CARES trial the rate of major adverse cardiovascular events was similar in febuxostat versus allopurinol treated patients (HR 1.03; 95% CI 0.87- 1.23), but a higher rate of cardiovascular deaths was observed (4.3% vs. 3.2% of patients; HR 1.34; 95% CI 1.03-1.73).

Please carefully study the information contained in the leaflet or, as applicable, on the outer packaging.

Please refer to for more information regarding price, more specific warnings etc.

Please note that the information you will find in this section is for healthcare professionals

Please confirm that you are a healthcare professional